Icon (ICLR) Projected to Announce Quarterly Earnings on Wednesday

Icon (NASDAQ:ICLR) is anticipated to announce its Q1 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of $2.55 per share and revenue of $2.0043 billion for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, June 24, 2026 at 8:00 AM ET.

Icon Stock Performance

Shares of Icon stock opened at $166.62 on Wednesday. The stock has a market cap of $12.76 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 8.16 and a beta of 1.22. The business has a fifty day simple moving average of $148.06 and a 200-day simple moving average of $136.46. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. Icon has a 12 month low of $66.57 and a 12 month high of $211.00.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ICLR shares. Barclays increased their price objective on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 25th. Citigroup lifted their target price on Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Robert W. Baird upped their target price on Icon from $168.00 to $186.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Leerink Partners set a $145.00 price target on shares of Icon in a research report on Thursday, May 28th. Finally, Truist Financial upgraded shares of Icon from a “hold” rating to a “buy” rating and raised their price target for the stock from $159.00 to $207.00 in a report on Tuesday, June 30th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $173.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Harris Associates L P acquired a new position in Icon in the 2nd quarter worth about $238,256,000. Wellington Management Group LLP grew its stake in shares of Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after buying an additional 975,268 shares in the last quarter. Boston Partners grew its stake in shares of Icon by 1,207.3% in the 3rd quarter. Boston Partners now owns 739,135 shares of the medical research company’s stock valued at $129,372,000 after buying an additional 682,597 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Icon in the second quarter worth approximately $94,814,000. Finally, JPMorgan Chase & Co. increased its holdings in Icon by 453.0% in the fourth quarter. JPMorgan Chase & Co. now owns 767,924 shares of the medical research company’s stock worth $139,931,000 after buying an additional 629,056 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.